BB Biotech AG Namen-Akt. 2.Linie BIOEE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CHF 40.95
- Day Range
- CHF 39.85–40.00
- 52-Week Range
- CHF 39.85–41.00
- Bid/Ask
- CHF 35.95 / CHF 40.00
- Market Cap
- CHF 2.19 Bil
- Volume/Avg
- 5,000 / 10,000
Key Statistics
- Price/Earnings (Normalized)
- 4.49
- Price/Sales
- 8.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.bbbiotech.com
Comparables
Valuation
|
Metric
|
BIOEE
|
HBMNE
|
BBN
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.49 | 37.43 | 14.37 |
Price/Book Value | 0.92 | 0.75 | 1.81 |
Price/Sales | 8.04 | 33.89 | 2.76 |
Price/Cash Flow | 22.31 | — | 10.11 |
Price/Earnings
BIOEE
HBMNE
BBN
Financial Strength
|
Metric
|
BIOEE
|
HBMNE
|
BBN
|
|---|---|---|---|
Quick Ratio | — | — | 5.08 |
Current Ratio | — | — | 5.47 |
Interest Coverage | — | — | 167.06 |
Quick Ratio
BIOEE
HBMNE
BBN
Profitability
|
Metric
|
BIOEE
|
HBMNE
|
BBN
|
|---|---|---|---|
Return on Assets (Normalized) | 8.82% | 1.92% | 8.59% |
Return on Equity (Normalized) | 10.04% | 2.10% | 10.63% |
Return on Invested Capital (Normalized) | — | — | 9.71% |
Return on Assets
BIOEE
HBMNE
BBN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gstsygqmt | Srzb | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Czzshxk | Mvsqq | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yjfmhlddg | Spwkrrz | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jtvpbpwfx | Lnvkyy | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Bjfwgmvk | Hwnz | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Smlgfptmn | Dmbc | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xvwykvlzn | Dkvh | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Rwhhrnxxl | Qght | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zcfpqjnb | Kfqbzv | $13.4 Bil | |||
| Incyte Corp
INCY
| Gkzdvkcvn | Cgtqqf | $12.7 Bil |
United States